The consortium assembled here will contribute to the development of new anti-inflammatory drugs for clinical use in the European Union and beyond by identifying medicinal plant extracts with NF-kappa inhibitory activity and/or inhibitory effects on targets of the inflammatory cascade in peripheral and CNStissues. These targets will include, for example, IL-1beta, TNFalpha, PGE2, and IL-6. Subsequently the compounds mediating this inhibitory effect will be isolated and their structure elucidated. The consortium has the capacity to evaluate the extracts in a large set of targets related to the transcriptional activation of gene products of relevance for inflammatory, immunomodulatory and apoptotic activity. Select compounds will be further studied in in-vivo as well as in-Microsystems and we expect that this research will form the basis for preclinical and clinical development.
Funding SchemeCSC - Cost-sharing contracts
SG1 2NY Stevenage
79104 Freiburg (In Breisgau)